trending Market Intelligence /marketintelligence/en/news-insights/trending/r_xeT16e9naMpXTxjs-y8Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

The U.S. FDA approved Imbruvica for the treatment of relapsed or refractory marginal zone lymphoma, a rare form of blood cancer.

The drug, which is jointly developed and commercialized by AbbVie Inc.'s Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech Inc., is already approved for patients with mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia blood cancers.